Fundz

Who to call at Nxera Pharma Ltd, and when

Fundz watches for the moments Nxera Pharma Ltd starts buying, and tells you who to reach.

  • An alert the day Nxera Pharma Ltd raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nxera Pharma Ltd, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nxera Pharma Ltd. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Nxera Pharma secured a $10 million milestone payment from Neurocrine Biosciences following IND acceptance for NBI-1117567 in a Phase 2 study. This funding will enhance Nxera's drug development initiatives.

Aug 26, 2026
TokyoBiotechnologyPharmaceutical

Description

Nxera Pharma has announced that it will receive a $10 million milestone payment from its partner Neurocrine Biosciences upon IND acceptance for the Phase 2 study of NBI-1117567. This milestone payment marks a significant advancement in Nxera's drug portfolio aimed at Alzheimer's cognition. The funds are expected to be recognized as revenue in Q3 FY2026. This development demonstrates Nxera's commitment to addressing significant medical needs in the field of Alzheimer's treatment.

Quick answer

Nxera Pharma secured a $10 million milestone payment from Neurocrine Biosciences following IND acceptance for NBI-1117567 in a Phase 2 study. This funding will enhance Nxera's drug development initiatives. (August 26, 2026). Nxera Pharma Ltd is based in Tokyo, Tokyo, Japan.

What agreement did Nxera Pharma Ltd announce on August 26, 2026?
Nxera Pharma has announced that it will receive a $10 million milestone payment from its partner Neurocrine Biosciences upon IND acceptance for the Phase 2 study of NBI-1117567. This milestone payment marks a significant advancement in Nxera's drug portfolio aimed at Alzheimer's cognition.
What does Nxera Pharma Ltd do?
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
Where is Nxera Pharma Ltd based?
Nxera Pharma Ltd is based in Tokyo, Tokyo, Japan.

Source: Fundz verified event record.

Company Information

Company

Nxera Pharma Ltd

Location

Tokyo, Tokyo, Japan

About

Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave” platform to provide a sustainable source of best- or first-in-class candidates.

Related People

Hironoshin
Likely contact at this company
••••••••@••••••••

See Hironoshin's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Nxera Pharma Ltd's next move

Learn about Strategic plan

Nxera Pharma Ltd signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.